M6A-modified circRBM33 promotes prostate cancer progression via PDHA1-mediated mitochondrial respiration regulation and presents a potential target for ARSI therapy

Chuanfan Zhong, Zining Long, Taowei Yang, Shuo Wang, Weibo Zhong, Feng Hu, Jeremy Yuen‐Chun Teoh, Jianming Lü, Xiangming MaoInternational Journal of Biological Sciences 2023 · DOI

Introduction

Prostate cancer (PCa) remains a leading cause of cancer-related mortality in men. While initial treatments like Androgen Deprivation Therapy (ADT) are often effective, many patients eventually progress to Castration-Resistant Prostate Cancer (CRPC). At this stage, tumors frequently become insensitive to standard Androgen Receptor Signaling Inhibitors (ARSIs) like enzalutamide. Recent research has highlighted "metabolic reprogramming" as a key driver of this progression, where PCa cells shift toward increased mitochondrial oxidative phosphorylation (OXPHOS) to fuel their growth. This study identifies the $m^6A$-modified circular RNA circRBM33 as a master regulator of this metabolic shift and a potential therapeutic target.

Identification and m6A Modification of circRBM33

To uncover the epigenetic drivers of PCa progression, researchers integrated public circRNA-seq data with $m^6A$-RNA Immunoprecipitation (MeRIP) sequencing. This multi-omics approach identified circRBM33 as a highly expressed, $m^6A$-modified circular RNA associated with poor clinical outcomes.

Validation of m6A modification on circRBM33 via MeRIP-PCR and enrichment analysis in PCa cell lines.

The circular nature of circRBM33 was confirmed through RNase R digestion and Actinomycin D treatment, which demonstrated its superior stability compared to linear transcripts. The study found that the $m^6A$ modification, added by the "writer" enzyme METTL3, acts as a molecular switch that enables circRBM33 to interact with the "reader" protein FMR1.

The circRBM33-FMR1-PDHA1 Axis

Unlike many circRNAs that act as miRNA sponges, circRBM33 functions as a protein scaffold. It recruits FMR1 to the mRNA of PDHA1 (Pyruvate Dehydrogenase E1 Subunit Alpha 1), a critical enzyme linking glycolysis to the tricarboxylic acid (TCA) cycle. By forming this complex, circRBM33 stabilizes PDHA1 mRNA, extending its half-life and significantly boosting mitochondrial respiration. This "supercharging" of the mitochondria increases the production of Acetyl-CoA and ATP, providing the energy necessary for rapid tumor growth and invasion.

Key Results and Clinical Significance

Clinical analysis revealed that high circRBM33 expression is strongly associated with higher Gleason scores and significantly shorter biochemical recurrence-free survival in patients.

Kaplan-Meier analysis demonstrating the correlation between high circRBM33 expression and reduced biochemical recurrence-free survival (p=0.022).

Functional assays showed that silencing circRBM33 reduced ATP production and the NADH/NAD+ ratio, effectively slowing tumor metabolism. Most importantly, the study found that circRBM33 regulates the expression of AR-V7, a splice variant of the androgen receptor that drives resistance to enzalutamide. In mouse models, knocking down circRBM33 restored sensitivity to ARSI therapy, with the combination of circRBM33 silencing and enzalutamide producing a synergistic reduction in tumor volume.

Conclusion

The discovery of the $m^6A$-modified circRBM33-FMR1-PDHA1 axis provides a new understanding of how metabolic reprogramming drives prostate cancer progression and drug resistance. Targeting this axis, perhaps through antisense oligonucleotides (ASOs) or small molecules that disrupt the circRBM33-FMR1 interface, offers a promising strategy for treating advanced, therapy-resistant prostate cancer.

Summary updated

Abstract

N6-Methyladenosine (m6A) is the most prevalent RNA modification in various types of RNA, including circular RNAs (circRNAs). Mounting evidence has shown that circRNAs may play critical roles in diverse malignancies. However, the biological relevance of m6A modification of circRNAs in prostate cancer (PCa) remains unclear and needs to be elucidated. Our data showed that circRBM33 was m6A-modified and was more highly expressed in PCa cells than in normal cells/tissues. The <i>in vitro</i> and <i>in vivo</i> experiments showed that downregulation/upregulation of circRBM33 inhibited/promoted tumour growth and invasion, respectively. Decreasing m6A levels rescued the tumour-promoting effect of circRBM33. Additionally, once modified by m6A, circRBM33 interacts with FMR1 by forming a binary complex that sustains the mRNA stability of PDHA1, a downstream target gene. Suppressed/overexpressed circRBM33 lowered/enhanced the ATP production, the acetyl-CoA levels and the NADH/NAD<sup>+</sup> ratio. Moreover, depletion of circRBM33 significantly increased the response sensitivity to androgen receptor signalling inhibitor (ARSI) therapy, including enzalutamide and darolutamide, in prostate tumours. Our study suggested that the m6A-mediated circRBM33-FMR1 complex can activate mitochondrial metabolism by stabilizing PDHA1 mRNA, which promotes PCa progression, and can attenuate circRBM33 increased ARSI effectiveness in PCa treatment. This newly discovered circRNA may serve as a potential therapeutic target for PCa.
BibTeX
@article{zhong2023m,
  author = {Chuanfan Zhong and Zining Long and Taowei Yang and Shuo Wang and Weibo Zhong and Feng Hu and Jeremy Yuen‐Chun Teoh and Jianming Lü and Xiangming Mao},
  title = {{M6A-modified circRBM33 promotes prostate cancer progression via PDHA1-mediated mitochondrial respiration regulation and presents a potential target for ARSI therapy}},
  journal = {International Journal of Biological Sciences},
  year = {2023},
  doi = {10.7150/ijbs.77133},
}
Figure